NICE must do better at summarising and communicating evidence on statinsBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5081 (Published 03 September 2014) Cite this as: BMJ 2014;349:g5081
- Ben M Goldacre, research fellow in epidemiology1
- 1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Rabar and colleagues’ summary of the National Institute for Health and Care Excellence (NICE) guideline on statins omits the key information clinicians need: the number needed to treat (NNT) with statins in different risk groups, at different levels of treatment intensity.1 This is not The BMJ’s shortcoming. NICE advises doctors to discuss this information with their patients, but it is missing from the NICE guideline itself.
The most attentive reader might find—in …